6 months later, NeuroVista completed its first phase of validation.
We never packaged the model as a miracle that could cure disease. It succeeded at only one thing: putting easily overlooked early risks in front of doctors sooner.
The night the first validation results came in, the team stayed in the conference room until the early hours of the morning.
Once all the data had finished running across the screen, Elena didn't rush to call the investors. She asked me first, "Do you think it's ready?"
I didn't answer immediately.
At DentAxis, every successful run had become another reason for Grant to demand more speed. This time, I could carefully review the final batch of results before deciding what came next.
"It's ready for the next phase," I said.
The room erupted in cheers. Someo
